Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Unicentric retrospective analysis of a cohort of 602 young adult and adolescent patients, aged 15 to 30 years, with haematological malignancies, and managed between 2000 and 2016
The therapeutic results (response and survival) of young adult and adolescent patients with hematological malignancies are generally lower than those usually observed in adults over the age of 30, with equivalent treatment, particularly in lymphomatous pathology.The overall analysis of this large cohort of patients in its entirety, then by age groups (15-17 years, 18-25 years, 26-30 years) and pathology aims to describe the future of patients and patients. compare them to the results of the literature observed in this age group, and according to the therapeutic regimens administered (pediatric regimen or adult regimen).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 15-17 years old | 15-17 years old |
| |
| 18-25 years old | 18-25 years old |
| |
| 26-30 years old | 26-30 years old |
| |
| acute leukemia | acute leukemia |
| |
| non-Hodgkin's lymphoma | non-Hodgkin's lymphoma |
| |
| Hodgkin lymphoma | Hodgkin lymphoma |
| |
| pediatric therapeutic regimen administered |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| administered therapeutic regimens | Drug | administered therapeutic regimens |
|
| Measure | Description | Time Frame |
|---|---|---|
| Global Survival | delay between the date of diagnosis and the date of the latest news | 15 years |
| Survival without event | delay between the date of diagnosis and an event (relapse, death, lost of follow-up) | 15 years |
| Progression-free survival | defined as the delay between the date of diagnosis and the date of relapse or death. | 15 years |
| Measure | Description | Time Frame |
|---|---|---|
| Epidemiological distribution by pathology compared to the adult population over 30 years | Epidemiological distribution by pathology compared to the adult population over 30 years | 1 day |
| Descriptive analysis of the characteristics of the disease at diagnosis by pathology |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
cohort of young adult patients and adolescents aged 15 to 30, carriers of hematological malignancies, and supported between 2000 and 2016
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Diane COSO | Institut Paoli-Calmettes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Paoli Calmettes | Marseille | Bouches Du Rhone | 13009 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
pediatric therapeutic regimen administered
|
| adult therapeutic regimen administered | adult therapeutic regimen administered |
|
| patients included in clinical trials | patients included in clinical trials |
|
| patients not included in clinical trials | patients not included in clinical trials |
|
Descriptive analysis of the characteristics of the disease at diagnosis by pathology |
| 15 years |
| Descriptive analysis of treatments by pathology | Descriptive analysis of treatments by pathology | 15 years |
| Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | 15 years |
| Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | 15 years |
| Progression-free survival (PFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | Progression-free survival (PFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | 15 years |
| Long-term toxicity analysis (second cancers, fertility) for the global cohort and pathology. | Long-term toxicity analysis (second cancers, fertility) for the global cohort and pathology. | 15 years |
| ID | Term |
|---|---|
| D008228 | Lymphoma, Non-Hodgkin |
| D006689 | Hodgkin Disease |
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided